AZD 4017

CAS No. 1024033-43-9

AZD 4017( AZD4017 )

Catalog No. M10111 CAS No. 1024033-43-9

AZD4017 is a potent, selective, and orally bioavailable human 11β-HSD1 with IC50 of 7 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 169 In Stock
5MG 155 In Stock
10MG 275 In Stock
25MG 549 In Stock
50MG 775 In Stock
100MG 1070 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    AZD 4017
  • Note
    Research use only, not for human use.
  • Brief Description
    AZD4017 is a potent, selective, and orally bioavailable human 11β-HSD1 with IC50 of 7 nM.
  • Description
    AZD4017 is a potent, selective, and orally bioavailable human 11β-HSD1 with IC50 of 7 nM, shows no significant activity against 11β-HSD1 and 17β-HSD1, 17β-HSD3 (IC50>30 uM); AZD4017 is inactive (<25% inhibition at 10 μM) against Cytochrome P450 enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4), and lower potency against the mouse, rat and dog 11β-HSD1 (IC50=750-4000 nM); demonstrates the dose dependent inhibition of 11β-HSD1 in vivo.Cushing Disease Phase 2 Clinical.
  • In Vitro
    AZD 4017 displays excellent selectivity versus the related enzymes 11-βHSD2, 17β-HSD1, 17β-HSD3 (all IC50>30 μM) and shows no measurable activity against the glucocorticoid and mineralocorticoid receptors. Despite having high potency for the human form of 11β-HSD1, AZD 4017 shows much reduced activity across species with the exception of cynomolgous monkey (IC50=0.029 μM). Additionally, as it is believed that adipose is a key target organ, inhibition of 11β-HSD1 activity is measured in isolated human adipocytes from nondiabetic volunteers. AZD 4017 is shown to be a potent inhibitor in this key target tissue (IC50=0.002 μM) in good agreement with the enzyme potency, thus providing some confidence that AZD 4017 is not restricted from adipose tissue by the fact that it was acidic.
  • In Vivo
    Since AZD 4017 has lower potency against the mouse enzyme, only a limited number of preclinical pharmacodynamic measurements are performed. Increasing the dose further led to a maximal effect of approximately 70% inhibition at 1500 mg/kg, equivalent to 10×IC50 in the mouse, demonstrating the dose dependent inhibition of 11β-HSD1 by AZD 4017 in this model.
  • Synonyms
    AZD4017
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    11β-HSD
  • Recptor
    11β-HSD
  • Research Area
    Endocrinology
  • Indication
    Cushing Disease

Chemical Information

  • CAS Number
    1024033-43-9
  • Formula Weight
    419.58
  • Molecular Formula
    C22H33N3O3S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (297.92 mM)
  • SMILES
    O=C(O)C[C@H]1CN(C2=NC(SCCC)=C(C(NC3CCCCC3)=O)C=C2)CCC1
  • Chemical Name
    2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Scott JS, et al. J Med Chem. 2012 Jun 28;55(12):5951-64.
molnova catalog
related products
  • INCB13739

    INCB13739 (INCB-13739) is a potent, selective, oral 11βHSD1 inhibitor (IC50=1.1 nM) with high seelctivity over other dehydrogenases, glucocorticoid and mineralocorticoid receptors.

  • SKI-2852

    A highly potent, selective, and orally bioavailable 11β-HSD1 inhibitor with IC50 of 2.9 and 1.6 nM for hHSD1 and mHSD1, respectively.

  • ASP3662

    ASP3662 is a potent, selective, CNS-penetrable and orally active inhibitor of 11β-HSD1 with Ki of 5.3, 2.6 and 23 nM for human, mouse and rat 11β-HSD1.